2CUREX AB SEK-10 Net Assets
2CUREX AB SEK-10 net assets. Based on the latest financial reports, 2CUREX AB SEK-10 (2QE) has net assets worth €626.00K EUR (≈ $731.86K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.18 Million ≈ $6.05 Million USD) and total liabilities (€4.55 Million ≈ $5.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 2CUREX AB SEK-10 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €626.00K |
| % of Total Assets | 12.09% |
| Annual Growth Rate | -60.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.0 |
Net Assets of 2CUREX AB SEK-10 (2021–2024)
Net assets of 2CUREX AB SEK-10 from 2021 to 2024. This chart illustrates how 2CUREX AB SEK-10's net assets have evolved over time, based on quarterly financial data. See 2CUREX AB SEK-10 balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for 2CUREX AB SEK-10 (2021–2024)
The table below shows the annual net assets of 2CUREX AB SEK-10 from 2021 to 2024. For live market cap and overall valuation, see 2CUREX AB SEK-10 stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €4.68 Million ≈ $5.47 Million |
-28.45% |
| 2023-12-31 | €6.54 Million ≈ $7.64 Million |
-84.81% |
| 2022-12-31 | €43.03 Million ≈ $50.31 Million |
-42.12% |
| 2021-12-31 | €74.34 Million ≈ $86.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to 2CUREX AB SEK-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9270000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
2CUREX AB SEK-10 Net Assets Breakdown (December 2024)
2CUREX AB SEK-10 net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €116.31 Million | 2486.94% |
| Total Equity | €4.68 Million | 100.00% |
2CUREX AB SEK-10 Competitors by Market Cap
The table below lists competitors of 2CUREX AB SEK-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Braemar Plc
LSE:BMS
|
$925.62K |
|
Lyc Healthcare Bhd
KLSE:0075
|
$928.88K |
|
Applied DNA Sciences, Inc.
NASDAQ:BNBX
|
$929.58K |
|
Satis Group S.A.
WAR:STS
|
$929.92K |
|
Pacific Bay Minerals Ltd
V:PBM
|
$923.30K |
|
PENTIXAPHARM HOLDING N AG
XETRA:PTP
|
$922.50K |
|
Alveen
PA:MLALV
|
$920.96K |
|
Cake Box Holdings PLC
LSE:CBOX
|
$920.81K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 2CUREX AB SEK-10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,537,000 to 4,677,000, a change of -1,860,000 (-28.5%).
- Net loss of 4,550,000 reduced equity.
- New share issuances of 2,690,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.55 Million | -97.28% |
| Share Issuances | €2.69 Million | +57.52% |
| Total Change | €- | -28.45% |
Book Value vs Market Value Analysis
This analysis compares 2CUREX AB SEK-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.25 | €0.04 | x |
| 2022-12-31 | €2.44 | €0.04 | x |
| 2023-12-31 | €0.37 | €0.04 | x |
| 2024-12-31 | €0.19 | €0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 2CUREX AB SEK-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.65x
- Recent ROE (-97.28%) is above the historical average (-194.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -25.47% | 0.00% | 0.00x | 1.06x | €-26.37 Million |
| 2022 | -69.18% | -33077.78% | 0.00x | 1.11x | €-34.07 Million |
| 2023 | -587.06% | 0.00% | 0.00x | 1.08x | €-39.03 Million |
| 2024 | -97.28% | 0.00% | 0.00x | 1.65x | €-5.02 Million |
Industry Comparison
This section compares 2CUREX AB SEK-10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 2CUREX AB SEK-10 (2QE) | €626.00K | -25.47% | 7.27x | $923.79K |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About 2CUREX AB SEK-10
2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient's metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.